Sacubitril/Valsartan - StatPearls - NCBI Bookshelf

Sacubitril/valsartan is the first agent to be approved in a new class of drugs called angiotensin receptor neprilysin inhibitor (ARNI). The medication is FDA-approved to treat patients with chronic heart failure with reduced ejection fraction (HFrEF) with NYHA class II, III, or IV. Sacubitril/valsartan is to be used in place of an ACEI or angiotensin II receptor blocker (ARB) and in conjunction with other standard, heart-failure treatments (beta-blocker, aldosterone antagonist). Patients must be able to tolerate ACEI or ARB before starting on sacubitril/valsartan. This activity outlines the indications, mechanism of action, methods of administration, important adverse effects, contraindications, toxicity, and monitoring, of sacubitril/valsartan, so providers can direct patient therapy in conditions where it is indicated, as part of the interprofessional team.

Sacubitril-Valsartan - StatPearls - NCBI Bookshelf The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation Bookshelf Search database Books All Databases Assembly Biocollections BioProject BioSample Books ClinVar Conserved Domains dbGaP dbVar Gene Gen

saved by

• Angela Yang

related reading

• Dilated Cardiomyopathy - StatPearls - NCBI Bookshelfncbi.nlm.nih.gov
• Peripheral Arterial Disease - StatPearls - NCBI Bookshelfncbi.nlm.nih.gov
• Arrhythmogenic Right Ventricular Cardiomyopathy | Cedars-Sinaicedars-sinai.org
• Edema formation in congestive heart failure and the underlying mechanismsncbi.nlm.nih.gov
• Guideline summary - Chronic Heart Failure in Adults - NCBI Bookshelfncbi.nlm.nih.gov
• 林世崇醫師 Alex Lin, MD, FACCmedclinical.wordpress.com
• Diabetic Nephropathy - StatPearls - NCBI Bookshelfncbi.nlm.nih.gov
• Press Release: Sanofi’s venglustat accepted for priority review in the US to treat type 3 Gaucher diseasesanofi.com
• Atrioventricular nodal reentrant tachycardia - UpToDateuptodate.com
• Warpspeed — Forecastswarpspeed.sh
• Levofloxacin - StatPearls - NCBI Bookshelfncbi.nlm.nih.gov
• Universal Definition and Classification of Heart Failure: A Step in the Right Direction from Failure to Function - American College of Cardiologyacc.org